GSA Capital Partners’s VistaGen Therapeutics VTGN Stock Holding History
Bought
Maintained
Sold
Other funds holding VTGN
GSA Capital Partners's VTGN Position: Q3 2026 in Review
GSA Capital Partners increased its VistaGen Therapeutics (VTGN) stake by 1,403% in Q3 2026, buying an estimated $194K and bringing the position to 820,312 shares worth $252K. The position accounts for 0.01% of the portfolio, ranked #1487.
GSA Capital Partners first reported a position in VTGN in Q3 2021 and has held it in 12 quarters since. The position peaked at $794K in Q3 2022. 42 funds tracked by Wall St. Rank hold VTGN as of Q3 2026.
- GSA Capital Partners held 820,312 shares of VistaGen Therapeutics worth $252K as of Q3 2026.
- GSA Capital Partners bought 765,728 VistaGen Therapeutics shares in Q3 2026, an estimated $194K.
- VistaGen Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q3 2026, its #1487 holding.
- GSA Capital Partners first reported a position in VistaGen Therapeutics in Q3 2021 and has held it in 12 quarters since.
- GSA Capital Partners's VistaGen Therapeutics position peaked at $794K in Q3 2022.
- 42 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2026.
Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.